XL 188

Cat. No.:	HY-122886
CAS No.:	2305045-76-3
Molecular Formula:	$C_{32}H_{42}N_6O_4$
Molecular Weight:	574.71
Target:	Deubiquitinase
Pathway:	Cell Cycle/DNA Damage
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (174.00 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	1.7400 mL	8.7000 mL	17.4001 mL
	5 mM	0.3480 mL	1.7400 mL	3.4800 mL
	10 mM	0.1740 mL	0.8700 mL	1.7400 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: 2.5 mg/mL (4.35 mM); Clear solution; Need ultrasonic
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: 2.5 mg/mL (4.35 mM); Clear solution; Need ultrasonic
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: 2.5 mg/mL (4.35 mM); Clear solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

XL 188 is a potent and selective USP7 inhibitor with IC_{50} values of 90 nM and 193 nM for USP7 full-length and catalytic domain enzyme, respectively. XL 188 can be used in research of cancer[1].

In Vitro

XL 188 (1-20 μM; 16 h; MCF7 cells) promotes USP7 dependent loss of HDM2 and increase of p53 and p21[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line:	MCF7 cells
Concentration:	1, 5, 10, and 20μM
Incubation Time:	16 hours
Result:	Had the loss of HDM2 accompanied by an increase in downstream tumor suppressors p21 and p53.

REFERENCES

[1]. Stolte B, et, al. Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in TP53 wild-type Ewing sarcoma. J Exp Med. 2018 Aug 6;215(8):2137-2155.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA